Malignancy-Associated Hemophagocytic Lymphohistiocytosis: Clinical Characteristics, Treatment Patterns, and Survival Outcomes in a Tertiary Care Center Cohort
Clinical Lymphoma Myeloma and Leukemia · 2026-09 · 26 (9) · e1133-e1144.e2
DOI: 10.1016/j.clml.2026.06.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-09. Verfasst von Ricardo Kosch und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Hematology and Bone Marrow Transplantation with Division of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg,…. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, Lymphoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Malignancy-associated hemophagocytic lymphohistiocytosis (M-HLH) carries a poor prognosis and is often complicated by overlapping infection, cytopenias, organ failure, and progressive disease. METHODS: We retrospectively analyzed 49 adults with M-HLH at a single tertiary cancer center (2013-2026), summarizing malignancy spectrum, diagnostic features, treatment, and survival outcomes. HLH probability was assessed by HScore and modified HLH-2004 criteria. RESULTS: Lymphoma was the main underlying disease (34/49; 69.4%), led by aggressive B-cell (17/49; 34.7%) and T-cell NHL (12/49; 24.5%). HLH coincided with initial malignancy recognition in 17 of 49 patients (34.7%). The median HScore was 231 (IQR 202-256); 44 of 49 patients (89.8%) met the ≥ 169 threshold, and 42 of 49 patients (85.7%) fulfilled ≥ 5 of 7 modified HLH-2004 criteria. HLH-directed therapy included corticosteroids (41/49; 83.7%), etoposide (21/49; 42.9%), and anakinra (16/49; 32.7%); 21 of 49 patients (42.9%) received concurrent malignancy-directed chemotherapy. Mortality was 59.2% (29/49) with a median overall survival of 56 days (median follow-up 612 days for the cohort; 574 days among survivors, n = 20). De novo presentation carried substantially lower mortality than HLH in previously known malignancy (23.5% vs. 78.1%; hazard ratio [HR] 5.38, 95% confidence interval [CI], 1.85-15.61; P = .002). Malignancy-directed chemotherapy was associated with lower mortality than HLH-directed therapy alone (HR 3.11, 95% CI, 1.36-7.09; P = .007). All 6 patients with invasive mold infection died. CONCLUSIONS: M-HLH was predominantly lymphoma-associated, met diagnostic criteria with high probability, and carried poor short-term survival. De novo presentation had better outcomes, likely because lymphoma-directed chemotherapy can simultaneously address the underlying malignant trigger and the hyperinflammatory state. Invasive mold infection was uniformly fatal, illustrating the lethal combination of profound immunosuppression and uncontrolled opportunistic infection in this setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Hematology and Bone Marrow Transplantation with Division of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Institute for Infection Research and Vaccine Development (IIRVD), Center for Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; I. Department of Medicine, University Medical Center Hamburg…
- Knowledge Technology Group, Department of Informatics, University of Hamburg, Hamburg, Germany.
- Department of Oncology, Hematology and Bone Marrow Transplantation with Division of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: m.al-bazaz@uke.de.
Zitieren
APA
Kosch, R., Alsdorf, W., Ahmadi, P., Hölzemer, A., Abdelrahim, A. G., Ahrens, K., Bokemeyer, C., Weisel, K., Sonnemann, P., & Al-Bazaz, M. (2026). Malignancy-Associated Hemophagocytic Lymphohistiocytosis: Clinical Characteristics, Treatment Patterns, and Survival Outcomes in a Tertiary Care Center Cohort. Clinical Lymphoma Myeloma and Leukemia, 26(9), e1133-e1144.e2. https://doi.org/10.1016/j.clml.2026.06.013
Vancouver
Kosch R, Alsdorf W, Ahmadi P, Hölzemer A, Abdelrahim AG, Ahrens K, et al. Malignancy-Associated Hemophagocytic Lymphohistiocytosis: Clinical Characteristics, Treatment Patterns, and Survival Outcomes in a Tertiary Care Center Cohort. Clinical Lymphoma Myeloma and Leukemia. 2026;26(9):e1133-e1144.e2. doi:10.1016/j.clml.2026.06.013
BibTeX
@article{Kosch2026,
author = {Kosch, Ricardo and Alsdorf, Winfried and Ahmadi, Paymon and Hölzemer, Angelique and Abdelrahim, Aiman Gamal and Ahrens, Kyra and Bokemeyer, Carsten and Weisel, Katja and Sonnemann, Piet and Al-Bazaz, Maximilian},
title = {Malignancy-Associated Hemophagocytic Lymphohistiocytosis: Clinical Characteristics, Treatment Patterns, and Survival Outcomes in a Tertiary Care Center Cohort},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
volume = {26},
number = {9},
pages = {e1133--e1144.e2},
doi = {10.1016/j.clml.2026.06.013}
}
EUVIMED